Literature DB >> 8067749

Effects of pentamidine isethionate on Saccharomyces cerevisiae.

G Ludewig1, J M Williams, Y Li, C Staben.   

Abstract

We used Saccharomyces cerevisiae as a model system in which to examine the mechanism of action of the anti-Pneumocystis drug pentamidine. Pentamidine at low concentrations inhibited S. cerevisiae growth on nonfermentable carbon sources (50% inhibitory concentration [IC50] of 1.25 micrograms/ml in glycerol). Pentamidine inhibited growth on fermentable energy sources only at much higher concentrations (IC50 of 250 micrograms/ml in glucose). Inhibition at low pentamidine concentrations in glycerol was due to cytostatic activity rather than cytotoxic or mutagenic activity. Pentamidine also rapidly inhibited respiration by intact yeast cells, although inhibitory concentrations were much higher than those inhibitory to growth (IC50 of 100 micrograms/ml for respiration). Pentamidine also induced petite mutations, although only at concentrations much higher than those required for growth inhibition. These results suggest that a function essential for respiratory growth is inhibited by pentamidine and that pentamidine affects mitochondrial processes. We propose the hypothesis that the primary cellular target of pentamidine in S. cerevisiae is the mitochondrion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8067749      PMCID: PMC188161          DOI: 10.1128/AAC.38.5.1123

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Crystal structure of a pentamidine-oligonucleotide complex: implications for DNA-binding properties.

Authors:  K J Edwards; T C Jenkins; S Neidle
Journal:  Biochemistry       Date:  1992-08-11       Impact factor: 3.162

2.  Inhibition of topoisomerases from Pneumocystis carinii by aromatic dicationic molecules.

Authors:  C C Dykstra; R R Tidwell
Journal:  J Protozool       Date:  1991 Nov-Dec

3.  Clinical usefulness of high-pressure liquid chromatographic determination of serum pentamidine in AIDS patients.

Authors:  B Vinet; R Comtois; A Gervais; C Lemieux
Journal:  Clin Biochem       Date:  1992-04       Impact factor: 3.281

4.  Pentamidine is an N-methyl-D-aspartate receptor antagonist and is neuroprotective in vitro.

Authors:  I J Reynolds; E Aizenman
Journal:  J Neurosci       Date:  1992-03       Impact factor: 6.167

5.  Microculture screening assay for primary in vitro evaluation of drugs against Pneumocystis carinii.

Authors:  J C Comley; R J Mullin; L A Wolfe; M H Hanlon; R Ferone
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

6.  Structure and DNA binding activity of analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine)

Authors:  M Cory; R R Tidwell; T A Fairley
Journal:  J Med Chem       Date:  1992-02-07       Impact factor: 7.446

7.  Inhibition of enzymes of polyamine back-conversion by pentamidine and berenil.

Authors:  P R Libby; C W Porter
Journal:  Biochem Pharmacol       Date:  1992-08-18       Impact factor: 5.858

8.  Inhibition of diamine oxidase from porcine kidney by pentamidine and other aminoguanidine compounds.

Authors:  J C Cubría; D Ordóñez; M L Alvarez-Bujidos; A Negro; A I Ortíz
Journal:  Comp Biochem Physiol B       Date:  1991

9.  Pentamidine sensitivity and resistance in Saccharomyces cerevisiae as a model for pentamidine effects on Pneumocystis carinii.

Authors:  C Hatfield; A Kasarskis; C Staben
Journal:  J Protozool       Date:  1991 Nov-Dec

10.  The yeast IMP1 gene is allelic to GAL2.

Authors:  T L Ulery; D A Mangus; J A Jaehning
Journal:  Mol Gen Genet       Date:  1991-11
View more
  16 in total

1.  In vitro activities of pentamidine, pyrimethamine, trimethoprim, and sulfonamides against Aspergillus species.

Authors:  Javier Afeltra; Jacques F G M Meis; Roxana G Vitale; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 2.  Antifungal activity of nonantifungal drugs.

Authors:  J Afeltra; P E Verweij
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-06-26       Impact factor: 3.267

3.  T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena.

Authors:  Eio Yamada; Hiroshi Nishikawa; Nobuhiko Nomura; Junichi Mitsuyama
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

4.  Mutations affecting a yeast mitochondrial inner membrane protein, pnt1p, block export of a mitochondrially synthesized fusion protein from the matrix.

Authors:  S He; T D Fox
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

5.  Pentamidine inhibits mitochondrial intron splicing and translation in Saccharomyces cerevisiae.

Authors:  Y Zhang; A Bell; P S Perlman; M J Leibowitz
Journal:  RNA       Date:  2000-07       Impact factor: 4.942

6.  Pentamidine inhibition of group I intron splicing in Candida albicans correlates with growth inhibition.

Authors:  K E Miletti; M J Leibowitz
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

7.  In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans.

Authors:  Javier Afeltra; Eric Dannaoui; Jacques F G M Meis; Juan L Rodriguez-Tudela; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

8.  DB75, a novel trypanocidal agent, disrupts mitochondrial function in Saccharomyces cerevisiae.

Authors:  Charlotte A Lanteri; Bernard L Trumpower; Richard R Tidwell; Steven R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Characterization of the PNT1 pentamidine resistance gene of Saccharomyces cerevisiae.

Authors:  G Ludewig; C Staben
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

Review 10.  Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.

Authors:  M P Barrett; D W Boykin; R Brun; R R Tidwell
Journal:  Br J Pharmacol       Date:  2007-07-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.